Table 4.
Main fecal rifamycin SV PK parametersa
| Interval (h) | No. of samples | Xf (μg) | Xf (% of dose) | dXf/dt (μg/h) | ΣXf (mg) (n = 22) | ΣXf (% of dose) (n = 22) |
|---|---|---|---|---|---|---|
| Predose | NC | NC | NC | 331.6 ± 69.0 | 82.9 ± 17.3 | |
| 0–24 | 19 | 74,559.8 ± 115,987.1 | 18.6399 ± 28.9968 | 3,106.7 ± 4,832.8 | ||
| 24–48 | 20 | 200,044.5 ± 134,718.6 | 50.0111 ± 33.6796 | 8,335.2 ± 5,613.3 | ||
| 48–72 | 22 | 84,148.3 ± 98,101.0 | 21.0371 ± 24.5253 | 3,506.2 ± 4,087.5 | ||
| 72–84 | 22 | 1,250.0 ± 2,856.5 | 0.3125 ± 0.7141 | 104.2 ± 238.0 |
a
Values are means ± SD. Shown are the fecal elimination (Xf) (expressed in μg and as a percentage), the rate of elimination (dXf/dt), and the total elimination (ΣXf) (expressed in mg and as a percentage) after a single oral dose of 400 mg of sodium rifamycin SV MMX under fasting conditions (n = 22). NC, not calculated.